Justin M. Watts MD

PubMed

• Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort op...
  Jorge E Cortes, Gail J Roboz, Maria R Baer, Brian A Jonas, Gary J Schiller
  Journal of Hematology & Oncology. 2025-01-16
• 2 citations
  Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
  Stéphane De Botton, Christian Récher, Jorge Cortes, Antonio Curti, Pierre Fenaux
  British Journal of Haematology. 2024-12-19
• 1 citations
  Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia.
  Justin M Watts, Simon J Shaw, Brian A Jonas
  Current Treatment Options in Oncology. 2024-11-01

Abstracts/Posters

• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
  Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Targeted Therapy in L... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all